Skip to main content
. 2018 Jun 22;2(4):319–326. doi: 10.1002/ags3.12183

Table 1.

Recurrence‐free survival after surgery in patients with chronic hepatitis C

Variable Number MST (days) Survival rate (years) P‐value
3 5 7
Age (years)
<65 21 3102 67 51 51 .72
≥65 38 1644 64 41 36
Gender
Female 11 1639 80 50 50 .60
Male 48 1339 61 42 38
Alcohol abuse
Presence 13 1319 53 35 23 .26
Absence 46 1784 69 47 47
Diabetes mellitus
Presence 17 1319 59 49 33 .44
Absence 42 1644 67 43 43
Obesity
Presence 18 731 30 22 22 <.01
Absence 41 1996 75 54 49
Dyslipidemia
Presence 12 NA 81 65 65 .22
Absence 47 1339 61 40 36
Hypertension
Presence 26 1303 50 35 28 .038
Absence 33 3102 76 51 51
HBc antibody
Positive 33 1639 74 43 43 .61
Negative 26 1784 52 46 39
Interval from IFNa (years)
≤5 39 1324 59 38 38 .22
>5 20 1996 77 55 47
T‐Bil (mg/dL)
<1.0 48 1339 60 41 38 .49
≥1.0 11 3102 82 53 53
Albumin (g/dL)
<4.0 14 1324 63 45 45 .88
≥4.0 45 1644 65 44 40
Platelet count (×104/mL)
<15 29 1319 62 41 35 .30
≥15 30 1784 68 48 48
ALT (IU/L)
>30 21 1784 68 46 46 .42
≤30 38 1639 63 42 37
α‐Fetoprotein (ng/mL)
>20 17 1784 55 46 46 .83
≤20 42 1639 69 43 38
Tumor size (cm)
>2.0 29 1303 54 45 45 .93
≤2.0 30 1644 75 38 30
Differentiation degreeb
Well, mod 45 1644 67 45 40 .72
Poor 14 1263 56 40 40
No. tumors
Single 50 1784 67 48 44 .075
Multiple 9 945 50 17 17
MVI
Presence 18 3102 59 59 59 >.99
Absence 41 1639 67 38 33
Hepatic steatosis
Positive 32 1319 56 43 37 .32
Negative 27 1784 75 46 46
Lobular inflammation
Positive 47 NA 62 41 41 .37
Negative 12 1324 75 64 54
Ballooning
Positive 24 1324 59 39 31 .33
Negative 35 1644 69 47 47
Liver cirrhosis
Presence 15 1028 44 44 44 .37
Absence 44 1644 72 44 40
Type of hepatic resection
Non‐anatomical 37 1303 51 25 25 .022
Anatomical 22 NA 79 66 60
a

Interval from the end of interferon therapy to the detection of hepatocellular carcinoma.

b

Tumor differentiation: well, well‐differentiated; mod, moderately differentiated; poor, poorly differentiated.

ALT, alanine aminotransferase; HBc, hepatitis B core; IFN, interferon; MST, median survival time; MVI, microvascular invasion; NA, not applicable; T‐Bil, total bilirubin.